Strong 1Q27 supports growth outlook

BLIS Technologies Limited
399 Moray Place, Dunedin, New Zealand, 9016
blis.co.nz
info@blis.co.nz
20 August 2026

Strong 1Q27 supports growth outlook

BLIS Technologies Limited (BLIS) delivered revenue of $5.1m, for the first quarter ended 30
June 2026 (1Q27), an increase of $1.5m, or up 42%, on the same period last year. 1Q27
EBITDA was a $1.1m profit compared to a $0.2m loss for 1Q26. The 1Q27 financial information
is unaudited and in New Zealand dollars.

B2B revenue was up 67% on 1Q26 driven by ingredient growth in Asia Pacific, strong Probi
royalties and private label sales into China, partially offset by weaker ingredient revenue in
Europe. Total B2C revenue was up 4% on 1Q26.

“We have had an exceptional start to the year, with record revenue and EBITDA. Although the
first quarter should not be annualised to a full year, we are comfortable with our current forecast
of 10%-15% revenue growth for FY27.” said Scott Johnson, CEO.

Ends

For further information, please contact:

Scott Johnson
CEO
+64 21 488 831


About BLIS Technologies Ltd

Delivering proven health benefits through evidence-based, advanced probiotics
BLIS Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut.
Combining innovation with evidence-based research and the highest quality production controls enables
the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath),
immune support, teeth and gum health and skin health. BLIS
®
products are sold throughout New Zealand
and in Asia, Europe and the USA. More information about BLIS Technologies Ltd can be found at
www.blis.co.nz.

Website: www.blis.co.nz
Instagram: @blisprobiotics #blisk12 #blism18 #blisq24
Facebook: @BLISProbiotics